FDA sets November decision date for Vertex's povetacicept in IgA nephropathy

Vertex Pharmaceuticals (Nasdaq: VRTX) has received confirmation that the US FDA has accepted its Biologics License Application (BLA) for povetacicept, an investigational dual BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) inhibitor, for the treatment of adults with immunoglobulin A nephropathy (IgAN). The agency has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026, under an accelerated approval pathway.

The BLA seeks accelerated approval based on proteinuria reduction as a surrogate endpoint — a pathway the FDA has previously applied to other IgAN therapies. Vertex said the submission covers povetacicept 80 mg administered subcutaneously once every four weeks via a low-volume autoinjector intended for at-home use. If the povetacicept BLA acceptance advances to approval, it would mark the company's first commercialized product in nephrology, expanding beyond its established cystic fibrosis and hematology franchises.

The BLA is supported primarily by a pre-specified Week 36 interim analysis from the ongoing RAINIER trial (NCT06564142), a global Phase III randomized, double-blind, placebo-controlled study enrolling 605 adults with IgAN. The trial evaluated povetacicept 80 mg subcutaneously every four weeks against placebo, on top of standard of care.

At Week 36, patients in the povetacicept arm achieved a 52% reduction from baseline in urine protein to creatinine ratio (UPCR), with a 49.8% UPCR reduction versus placebo (P < 0.0001). The trial also met both secondary endpoints: a 77.4% reduction from baseline in serum galactose-deficient IgA1 (Gd-IgA1) compared to a +9.1% increase in the placebo group, and hematuria resolution in 85.1% of treated patients with baseline hematuria versus 23.4% in the placebo arm. The final analysis, with a primary endpoint of total estimated glomerular filtration rate slope through Week 104, is ongoing.

Earlier Phase I/II data from the RUBY-3 basket study provided supporting evidence, with the 80 mg cohort showing a 64% decrease from baseline in mean 24-hour UPCR and eGFR stabilization at 48 weeks.

Povetacicept is a dual BAFF+APRIL inhibitor engineered with a modified TACI (transmembrane activator and CAML interactor) domain, designed to block both cytokines that drive autoreactive B cell activity implicated in IgAN pathogenesis. The IgAN treatment landscape has expanded considerably in recent years, with Travere Therapeutics' sparsentan (Filspari) and Calliditas Therapeutics' budesonide (Tarpeyo) both carrying accelerated approvals based on proteinuria endpoints, and Novartis's iptacopan (Fabhalta) approved on a complement pathway mechanism. Povetacicept adds to this competitive field as the only dual BAFF+APRIL inhibitor currently in pivotal trials across multiple kidney diseases, with the Phase II/III OLYMPUS trial ongoing in primary membranous nephropathy.

---

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

---

Spot something wrong? Report an issue with this article